ATE243760T1 - Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen - Google Patents

Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen

Info

Publication number
ATE243760T1
ATE243760T1 AT95916864T AT95916864T ATE243760T1 AT E243760 T1 ATE243760 T1 AT E243760T1 AT 95916864 T AT95916864 T AT 95916864T AT 95916864 T AT95916864 T AT 95916864T AT E243760 T1 ATE243760 T1 AT E243760T1
Authority
AT
Austria
Prior art keywords
carcinomas
treatment
types
minimal residual
micrometastasization
Prior art date
Application number
AT95916864T
Other languages
English (en)
Inventor
Rudolf Henrikus Brakenhoff
Dongen Augustina Antonius Van
Original Assignee
Stichting Keel Neus En Oorheel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Keel Neus En Oorheel filed Critical Stichting Keel Neus En Oorheel
Application granted granted Critical
Publication of ATE243760T1 publication Critical patent/ATE243760T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95916864T 1995-05-10 1995-05-10 Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen ATE243760T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1995/000168 WO1996035808A1 (en) 1995-05-10 1995-05-10 Methods for detection and therapy of squamous cell carcinoma and bladder carcinoma, in particular for determining the presence and treatment of minimal residual disease, micrometastases or dissemination of such carcinoma types

Publications (1)

Publication Number Publication Date
ATE243760T1 true ATE243760T1 (de) 2003-07-15

Family

ID=19865519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916864T ATE243760T1 (de) 1995-05-10 1995-05-10 Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen

Country Status (5)

Country Link
EP (1) EP0828852B1 (de)
AT (1) ATE243760T1 (de)
AU (1) AU2375895A (de)
DE (1) DE69531167D1 (de)
WO (1) WO1996035808A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
AU6394399A (en) 1998-09-18 2000-04-10 Rockefeller University, The Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
GB201213652D0 (en) * 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target

Also Published As

Publication number Publication date
EP0828852A1 (de) 1998-03-18
EP0828852B1 (de) 2003-06-25
DE69531167D1 (de) 2003-07-31
AU2375895A (en) 1996-11-29
WO1996035808A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
Stanley et al. Identification and partial characterization of pemphigoid antigen extracted from normal human skin
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE299180T1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
ATE165980T1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
DE69839123D1 (de) Prostattumor polynukleotid- und antigenzusammensetzungen
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000001813A3 (en) Peptide inhibitors of androgen-independent activation of androgen receptor
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
DE69331813T2 (de) Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
ATE243760T1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001051513A3 (en) Ovarian tumor-associated sequences
DE69739653D1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
NO962596L (no) Nytt tumorsupressorgen
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
Pischel et al. Further evidence for structural relatedness between murine MHC and thymus-leukemia antigens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties